How much does Medicines Discovery Catapult Limited make?

Medicines Discovery Catapult Limited reported revenue of £21.8m and a loss of £209k in the year to 31 Mar 2026, according to its accounts filed at Companies House.

How many employees does Medicines Discovery Catapult Limited have?

Medicines Discovery Catapult Limited reported an average of 152 employees in the year to 31 Mar 2026.

Is Medicines Discovery Catapult Limited profitable?

No — Medicines Discovery Catapult Limited reported a loss of £209k in the year to 31 Mar 2026.

Company No. 09928547 · Incorporated 23 Dec 2015

Medicines Discovery Catapult Limited

Registered name: MEDICINES DISCOVERY CATAPULT LIMITED

Medicines Discovery Catapult Limited made £21.8m revenue and a £209k loss in the year to 31 Mar 2026.

Medicines Discovery Catapult Limited’s revenue grew 17% to £21.8m in the year to 31 Mar 2026, with a loss of £209k and 152 employees. The company is classified under “research and experimental development on biotechnology” and is based in Macclesfield; we hold 2 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 72110Research and experimental development on biotechnology

Status: Active
Location: Macclesfield, North West
Age: 10 yrs · since 2015
Type: PRI/LTD BY GUAR/NSC (Private, limited by guarantee, no share capital)

Non-profit. It is limited by guarantee (typically an association, club or management company), so it isn't run for profit. It is excluded from our opportunity lists.

Latest accounts · year to 31 Mar 2026

Key figures

Independent

Revenue

£21.8m

Growth ▲16.8%

Profit

−£209k

Growth —

Profit margin

−1%

Gross 67.4%

Employees

152

Change ▲2%

Profit / employee

−£1.4k

Revenue/employee £144k

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

2 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Mar 2025	31 Mar 2026
Disclosure	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£18.7m	£21.8m
Cost of sales	−£6.2m	−£7.1m
Gross profit	£12.5m	£14.7m
Operating profit	−£2.8m	−£1.5m
Profit before tax	−£946k	−£147k
Profit after tax	−£1m	−£209k
Profit (best available)	−£1m	−£209k
Employees (average)	149	152
Ratios
Profit margin	−5.5%	−1%
Gross margin	67%	67.4%
Revenue per employee	£125k	£144k
Profit per employee	−£6.9k	−£1.4k
Growth (year on year)
Revenue growth	—	▲16.8%
Headcount growth	—	▲2%
Balance sheet — indirect signals, not revenue
Net assets	—	—
Source	Accounts · bulk data Sep 2026	Accounts · bulk data Sep 2026

Derived from the latest filing

How the business works

Profit margin: −1%; Profit ÷ revenue.
Gross margin: 67.4%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £144k; Revenue ÷ average employees.
Profit per employee: −£1.4k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: —; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: —; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: —; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now —
Cash at bank: —; Now —
Headcount: ▲2%; Now 152
Deferred income: —; Now —
Fixed assets: —; Now —

Corporate ownership

Group structure

Subsidiaries (2)

Medicines Discovery Catapult Services Commercial LimitedRev. £5.2m · Profit £1.5m
Medicines Discovery Ventures LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from accounts for the year to 31 Mar 2026 (profit −£209k), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.